Diagonal Bio AB (DIABIO) — Cash Flow Reinvestment Rate
Latest as of March 2024:
0.08x
Diagonal Bio AB (DIABIO) has a Cash Flow Reinvestment Rate of 0.08x as of March 2024, reinvesting Skr541.00K (capex Skr0.00 plus investments Skr-541.00K) from operating cash flow of Skr6.57 Million. See Diagonal Bio AB balance sheet independence to measure how much of total assets are equity-financed.
Reinvestment Rate
0.08x
(Capex + Investments) / Operating CF
Total Reinvested
Skr541.00K
Capex + Investments
Operating Cash Flow
Skr6.57 Million
SEK
Capital Expenditures
Skr0.00
SEK
Diagonal Bio AB Cash Flow Reinvestment Rate (2020–2020)
Historical reinvestment intensity for Diagonal Bio AB across 1 annual periods. Also explore DIABIO current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Diagonal Bio AB (2020–2020)
Year-by-year capital reinvestment analysis for Diagonal Bio AB. For live market cap and broader valuation context, see DIABIO company net worth.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 0.00x | Skr0.00 | Skr226.67K | Skr0.00 | — |
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow